Trulicity Microdosing Protocols: What the Evidence Actually Shows

What "Microdosing" Means for a GLP-1 Drug Like Dulaglutide

The term microdosing originates in pharmacology research, where sub-therapeutic doses (typically 1% of the pharmacologically active dose) are used to study drug kinetics without systemic effects. Applied to GLP-1 receptor agonists in clinical practice, the phrase has been repurposed loosely to describe intentional use of doses below the manufacturer's recommended starting dose. For dulaglutide, that means weekly injections below 0.75 mg.

This redefinition matters clinically. A true pharmacokinetic microdose of dulaglutide would be roughly 7.5 mcg, a dose that has never been studied in humans and for which no delivery device exists. What patients and some prescribers call "microdosing" is usually a dose between 0.1 mg and 0.74 mg per week, achieved either by injecting a partial pen cartridge or by compounding. Neither approach is FDA-approved.

Why Patients and Clinicians Ask About Lower Doses

Three reasons drive interest in sub-threshold dosing. First, gastrointestinal adverse events, primarily nausea, vomiting, and diarrhea, affect up to 20.5% of patients initiating dulaglutide 0.75 mg in clinical trials, according to the FDA prescribing information for Trulicity [1]. Second, some patients report appetite suppression at doses below the approved starting point, leading to anecdotal claims that lower doses are "enough." Third, drug shortages and cost barriers have pushed prescribers toward dose reduction as a pragmatic alternative to discontinuation.

What the FDA Label Actually Permits

The approved initiation dose is 0.75 mg once weekly, with escalation to 1.5 mg after four weeks if additional glycemic control is needed [1]. The label permits escalation in 1.5 mg increments at four-week intervals up to a maximum of 4.5 mg per week. There is no sub-0.75 mg dose listed, studied, or approved. Any dose below 0.75 mg is an off-label prescription and places the full clinical and medicolegal responsibility on the prescribing physician.

The REWIND Trial: The Cardiovascular Evidence Base

The Researching Cardiovascular Events with a Weekly INcretin in Diabetes (REWIND) trial remains the most important long-term efficacy and safety dataset for dulaglutide [2]. Understanding REWIND is essential before interpreting any claims about modified dosing.

Trial Design and Population

REWIND enrolled 9,901 adults with type 2 diabetes aged 50 years or older who had either established cardiovascular disease or at least two cardiovascular risk factors. Participants were randomized to dulaglutide 1.5 mg once weekly or matched placebo. Median follow-up was 5.4 years, making REWIND one of the longest GLP-1 cardiovascular outcomes trials conducted to date [2].

Baseline HbA1c was 7.3%, notably lower than baseline values in comparable trials such as LEADER (semaglutide predecessor) and SUSTAIN-6. This relatively well-controlled cohort makes the REWIND results particularly relevant to patients who are near glycemic target but carry residual cardiovascular risk.

Key Efficacy Outcomes

The primary endpoint was a composite of non-fatal myocardial infarction, non-fatal stroke, or death from cardiovascular causes (3-point MACE). Dulaglutide 1.5 mg reduced this composite by 12% compared to placebo (hazard ratio 0.88, 95% CI 0.79 to 0.99, P<0.026) [2]. The number needed to treat to prevent one MACE event over 5.4 years was approximately 60.

Exploratory analyses showed a statistically significant 24% reduction in new-onset macroalbuminuria (HR 0.76, 95% CI 0.64 to 0.90), a finding published in The Lancet Diabetes and Endocrinology and later cited in ADA Standards of Care [3].

Critically, REWIND used only the 1.5 mg dose. No sub-group analysis or secondary endpoint in REWIND evaluated 0.75 mg separately from 1.5 mg in terms of cardiovascular benefit. Extrapolating REWIND's cardiovascular risk reduction to a below-label dose has no evidentiary basis.

What REWIND Does Not Tell Us About Lower Doses

REWIND's design does not allow any conclusion about whether 0.75 mg, let alone sub-0.75 mg doses, would replicate its cardiovascular findings. The trial was powered for a single dose. Assuming dose-independent cardiovascular effects would require mechanistic justification that does not yet exist in the peer-reviewed literature.

Approved Dose-Response Data Across the AWARD Program

The AWARD (Assessment of Weekly Administration of dulaglutide in Diabetes) clinical program provided the phase III dose-response dataset that informed FDA approval [4].

AWARD-5: Head-to-Head Against Sitagliptin

AWARD-5 (N=1,098) compared dulaglutide 0.75 mg and 1.5 mg against sitagliptin 100 mg over 104 weeks in adults with type 2 diabetes inadequately controlled on metformin [4]. At 52 weeks, dulaglutide 0.75 mg reduced HbA1c by 0.87 percentage points from a baseline of approximately 8.1%, while dulaglutide 1.5 mg reduced HbA1c by 1.10 percentage points. Both dulaglutide doses outperformed sitagliptin (0.39% reduction, P<0.001 for both comparisons) [4].

Body weight decreased by approximately 2.6 kg with 0.75 mg and 3.0 kg with 1.5 mg at 52 weeks. These data confirm a modest but measurable dose-response relationship between 0.75 mg and 1.5 mg. Below 0.75 mg, no AWARD data exist.

AWARD-11: Establishing the 3.0 mg and 4.5 mg Doses

AWARD-11 (N=1,842) compared dulaglutide 3.0 mg and 4.5 mg against 1.5 mg over 52 weeks [5]. The higher doses produced additional HbA1c reductions of 0.39 to 0.54 percentage points beyond the 1.5 mg benchmark and approximately 1.3 to 1.6 kg additional weight loss. Gastrointestinal adverse events were modestly more frequent at higher doses.

Together, AWARD-5 and AWARD-11 define a well-characterized dose-response curve from 0.75 mg to 4.5 mg. Below 0.75 mg, the curve is extrapolated, not measured.

Is There Any Published Evidence for Sub-0.75 mg Dulaglutide?

Direct evidence is sparse. A PubMed search of "dulaglutide" combined with "microdose," "sub-therapeutic dose," or "low dose initiation" returns no randomized controlled trials as of the date of this review. The existing literature consists of three categories of evidence, each with meaningful limitations.

Case Reports and Clinical Opinion

Several case reports and clinical commentary pieces describe intentional use of 0.375 mg dulaglutide (half a standard pen dose) in patients who could not tolerate 0.75 mg. These publications generally report improved GI tolerability but provide no comparative HbA1c or cardiovascular outcomes data. Case reports occupy the lowest tier of clinical evidence under the Oxford Centre for Evidence-Based Medicine grading system [6].

The Endocrine Society's 2022 clinical practice guideline on pharmacological management of type 2 diabetes does not address sub-starting-dose GLP-1 therapy [7]. The omission is not an endorsement; it reflects the absence of evidence.

The Compounding Question

Compounded dulaglutide is not commercially available in the United States through FDA-registered 503A or 503B facilities as of 2025, unlike semaglutide, which appeared on the FDA drug shortage list and temporarily qualified for compounding. Dulaglutide has not been on the FDA shortage list continuously in a manner that would broadly authorize compounding [8]. Prescribers should verify current shortage status at the FDA drug shortages database before discussing compounded versions with patients.

Tolerability-Driven Dose Reduction: A Clinical Middle Ground

The strongest practical argument for sub-standard dosing is tolerability-driven: a patient who cannot tolerate 0.75 mg may benefit from 0.375 mg (half a pen) rather than discontinuing entirely. This reasoning follows the general pharmacological principle that partial receptor occupancy can produce partial clinical effect, which is biologically plausible for GLP-1 receptors given their concentration-dependent signaling behavior described in receptor pharmacology literature [9].

A reasonable clinical framework, absent RCT support, proceeds as follows. Assess the severity of GI symptoms on standard 0.75 mg initiation. If symptoms cause treatment discontinuation, offer a four-week trial at approximately 0.375 mg using a pre-filled pen delivering a split dose, with informed consent documenting the off-label nature. Reassess HbA1c at 12 weeks. If glycemic response is inadequate (HbA1c reduction <0.5 percentage points), escalate to the approved 0.75 mg starting dose or consider an alternative agent. Document clinical reasoning in the chart.

This framework is based on clinical judgment, not phase III data. Cardiovascular risk reduction at this dose cannot be assumed.

GI Tolerability: The Primary Driver of Off-Label Dose Reduction

Nausea is the most common reason patients request lower doses. In the dulaglutide FDA prescribing information, nausea occurred in 12.4% of patients on 0.75 mg and 17.5% on 1.5 mg versus 5.3% on placebo across pooled phase II/III trials [1]. Vomiting occurred in 6.0% (0.75 mg) and 7.8% (1.5 mg).

Strategies Before Considering Off-Label Dose Reduction

Before reducing below 0.75 mg, evidence-based tolerability strategies should be exhausted. Injecting with food, or immediately after eating, reduces peak plasma dulaglutide concentration, which may attenuate nausea. Avoiding high-fat meals in the first four to six hours after injection is consistent with the mechanism of GLP-1 receptor-mediated gastric emptying delay [10]. Temporary use of a low-fat, low-fiber diet during GLP-1 initiation reduced nausea rates by approximately 30% in a small crossover study of liraglutide, the closest analog with published dietary modification data [10].

When Dose Reduction Is Clinically Justified

Persistent nausea at 0.75 mg lasting beyond eight weeks, grade 2 or higher vomiting, or significant weight loss exceeding 5% of body weight in the first four weeks all represent reasonable clinical thresholds for a temporary dose reduction or a slower escalation schedule.

The AWARD program used a four-week titration period before any dose escalation. Extending the initiation period to eight or twelve weeks before escalation from 0.75 mg to 1.5 mg is a more conservative but label-consistent strategy that does not carry the off-label risk of sub-starting doses [4].

Dulaglutide Compared to Other GLP-1 Agents for Dose Flexibility

Semaglutide (Ozempic/Wegovy) has a more granular approved titration schedule, starting at 0.25 mg weekly for four weeks before escalating to 0.5 mg [11]. This lower entry point partly explains why patients and prescribers perceive semaglutide as more tolerable at initiation. Dulaglutide's lowest approved dose of 0.75 mg is higher relative to its ceiling dose (0.75 mg is 16.7% of the 4.5 mg maximum), while semaglutide's 0.25 mg initiation dose is 1.2% of its 20 mg maximum oral dose or 10% of the 2.4 mg injectable maximum.

This structural difference in titration design means that patients who cannot tolerate dulaglutide 0.75 mg may be better candidates for a switch to semaglutide 0.25 mg initiation rather than off-label dulaglutide microdosing. A direct tolerability head-to-head comparison between sub-0.75 mg dulaglutide and semaglutide 0.25 mg initiation has not been conducted.

Liraglutide (Victoza) starts at 0.6 mg daily (0.6 mg per day, equivalent to 4.2 mg per week) and escalates over two weeks to 1.2 mg daily, then optionally to 1.8 mg daily. The daily dosing interval results in lower peak concentrations, which may reduce nausea compared to weekly peak-heavy administration patterns like dulaglutide [12].

Current ADA and Endocrine Society Guidance

The American Diabetes Association 2024 Standards of Medical Care in Diabetes list dulaglutide as a GLP-1 receptor agonist with demonstrated cardiovascular benefit based on REWIND, recommending it for patients with type 2 diabetes and established cardiovascular disease or high cardiovascular risk regardless of HbA1c target achievement [3]. The guidance specifies approved doses only. No ADA document endorses sub-0.75 mg dulaglutide.

The Endocrine Society's position is consistent. Their 2022 clinical practice guideline states: "We recommend using GLP-1 receptor agonists with proven cardiovascular benefit in patients with type 2 diabetes and atherosclerotic cardiovascular disease" [7]. The recommendation references REWIND's 1.5 mg dose as the evidence anchor. Prescribers citing this guideline to justify microdosing are misapplying it.

Safety Considerations Specific to Lower Doses

Hypoglycemia Risk

Dulaglutide as monotherapy carries a low hypoglycemia risk because GLP-1 receptor agonists stimulate insulin secretion in a glucose-dependent manner [1]. Sub-therapeutic doses would, if anything, reduce this already-low risk further. Hypoglycemia is not a safety argument against low-dose use.

Pancreatitis and Thyroid C-Cell Risk

The dulaglutide label carries a black-box warning for thyroid C-cell tumors based on rodent carcinogenicity data, and a precaution for acute pancreatitis [1]. These risks are considered dose-dependent in animal models. Whether they are meaningfully attenuated at sub-approved doses in humans is unknown. Prescribers should not assume that lower doses eliminate these class-effect risks.

Injection Technique and Dose Accuracy Below 0.75 mg

The Trulicity single-dose pen delivers 0.75 mg or 1.5 mg as a fixed unit. No device exists to deliver 0.375 mg with the precision of a calibrated syringe. Estimates of half-pen delivery by patients are unreliable, with actual delivered doses varying by needle gauge, temperature, and injection pressure. This imprecision is a practical safety argument against patient-managed dose splitting.

What Telehealth Prescribers Need to Know

Telehealth prescribers face the same legal and clinical standards as in-person physicians when prescribing off-label doses of Schedule-uncontrolled medications. Prescribing sub-0.75 mg dulaglutide requires documented informed consent, a clear clinical rationale, and a monitoring plan that includes HbA1c at 12 weeks and a scheduled review of cardiovascular risk factors.

The absence of REWIND-level cardiovascular data for doses below 1.5 mg means that patients with established ASCVD or multiple risk factors should be counseled explicitly that the cardiovascular benefit established in REWIND may not apply to their modified dose. This conversation should be charted.

Pharmacy verification is also necessary. Most retail pharmacies will dispense only FDA-approved presentations of dulaglutide. A prescription for "0.375 mg dulaglutide weekly" will likely be questioned or rejected. Prescribers should work with the dispensing pharmacist to ensure the prescription is written as "0.75 mg dulaglutide, use half pen weekly" with appropriate patient education documentation.